ZyVersa Therapeutics shares are trading higher after the company announced the European Patent Office granted a patent covering the company's Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease.
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics has been granted a patent by the European Patent Office for its Phase 2a-ready Cholesterol Efflux Mediator VAR 200, intended for use in diabetic nephropathy/diabetic kidney disease. This news has led to an increase in the company's stock price.
July 07, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ZyVersa Therapeutics' stock price has increased following the announcement of a granted patent for its Phase 2a-ready drug for diabetic kidney disease.
The granting of a patent for ZyVersa's Phase 2a-ready drug is a significant milestone for the company, as it provides protection for their intellectual property and allows them to exclusively market the drug in Europe. This positive news has led to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100